Publications by authors named "Lea Sequier"
Clinical experience of using biosimilars in Crohn's disease and their effectiveness.
Expert Opin Biol Ther
October 2024
Article Synopsis
- The approval of biosimilars for treating inflammatory bowel diseases (IBDs) helps address rising healthcare costs and improve treatment availability, particularly for Crohn's disease (CD).
- Since 2013, many biosimilars have been approved in Europe, with substantial clinical studies demonstrating their effectiveness in CD treatment across a diverse patient population.
- Experts recommend integrating biosimilars into standard clinical practice due to their proven efficacy and safety, as evidenced by significant increases in usage rates for infliximab and adalimumab in European countries.
Background: Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.
Aims: To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.
Methods: We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023.